Offsite manufacturer McAvoy has made moves to push into the pharmaceutical and life science construction sector.
The UK and Ireland-based company has created a new senior role, Pharmaceutical Strategy Lead, to promote growth in this sector.
McAvoy has chosen 15 year pharmaceutical and healthcare veteran, Andy Myers.
Myers brings extensive expertise in business development and client relationship management. He will support the next phase of McAvoy’s strategic growth in the sector, working with clients to deliver modular buildings for cleanrooms, laboratories, research centres, office spaces and science parks – whether for permanent facilities or temporary use.
In recent months, McAvoy has completed several projects in the sector, including the Collaborative Research and Innovation Centre at Porton Science Park.
Porton Science Park, located at the Porton Down Science Campus in South Wiltshire, provides a platform for health, life sciences and defence technology-related SMEs to innovate and collaborate.
Having Myers' expertise is all part of McAvoy’s strategy to build on its growing track record in the pharmaceutical and life sciences sectors.
Myers said: “Speed, efficiency, and sustainability are critical in the pharmaceutical sector, and McAvoy’s compelling turnkey design and build value proposition aligns well with the needs of this market. I’m looking forward to expanding the reach of the work we do at what is a crucial time, as demand for high-performance facilities continues to grow.”
Stephen Clayton, Preconstruction Director at McAvoy, said: “This appointment reflects our wider investment and expansion plans to bring more of our high-quality space solutions to the pharmaceutical and life sciences sectors. As demand for new facilities increases, we know modular construction will play an increasingly vital role.”